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Peer reEditorial‘Osteoporosis and Sarcopenia’ is a new journal for bone
and muscle diseases focusing on the Asian countries repre-
sented by the ‘Asian Federation of Osteoporosis Societies
(AFOS)’. Several journals covering osteoporosis or sarcopenia
presently exist, but they focus mainly on Western countries.
‘Osteoporosis and Sarcopenia’ will be unique due to its Asia-
centric emphasis, where both the number and age of the
population are rapidly increasing.
AFOSwas organized in 2008 and the ScientificMeetings had
been held at Guangzhou (2009), Kobe (2011), and Seoul (2013).
During the SeoulMeeting, the AFOSCouncilMembers decided
to launch a journal by consensus. Thereafter contribution for
submission of papers and financial support has been discussed.
The First Editorial Board Meeting for the AFOS Journal had
been held on November 2014 in Seoul. Regular monthly on-line
editorial board communications began in December of 2014.
This year 4th Scientific Meeting and 2nd Editorial Board
Meeting will be held in Macau on October.
In this, the inaugural issue, three review papers and six
original articles will be published.
Regarding the review papers,
Professor Langdahl of the Aarhus University introduced the
new drugs in development, including cathepsin K inhibitors
and sclerostin antibodies. She described both clinical and pre-
clinical data for the effects of Odanacatib and Ono-5334 as
compared with an alendronate control. Also, the efficacy and
safety of Romosozumab and Blosozumab versus teriparatide
were presented. Doctor Langdahl also suggested a possible
mechanism of action for these medicines on osteoblasts,
osteocytes, and osteoclasts with illustrations [1].
Doctor Shiraki and colleagues of Japan comprehensively
reviewed the role of vitamin K and dependent proteins on both
skeletal and extra-skeletal tissues. Authors described a finding
that vitaminK deficiencywas associatedwith fragility fractures,
energy metabolism, vascular calcification, and cancer [2].
Professor Klein of the University of Texas described steroid
induced osteoporosis and sarcopenia in animals and humans.
He proposed that various cytokines and inflammatory markers
of oxidative stress are involved in both bone and muscle
wasting [3].x.doi.org/10.1016/j.afos.2015.07.010
255/© 2015 The Korean Society of Osteoporosis. Production and hosting by
reativecommons.org/licenses/by-nc-nd/4.0/).
view under responsibility of The Korean Society of Osteoporosis.In terms of original articles,
Matsumoto et al. showed that fall incidencewas significantly
related to knee joint osteoarthritis and gait variability of osteo-
porotic patients in a population-based prospective study [4].
Harada et al. revealed that muscle (appendicular skeletal
muscle and lower limb muscle) mass increased after 1 year of
treatment with alendronate compared to a control [5].
Iwamoto et al. compared the effects of PTH (teriparatide)
with alendronate plus alfacalcidol in the real world, and
described responses in bone mineral density and biochemical
markers during 2 years of treatment [6].
Amphansap et al. confirmed that the one year mortality after
hip fractures was significantly higher in a non-surgical group
than in a surgical group in a hospital-based cohort study [7].
Heo et al. reported that sacral insufficiency fractures which
associated with lumbar spine compression fractures were
significantly higher in older patients with osteoporosis [8].
Finally, Kim et al. suggested that the high fragility fracture
rate in Parkinson's disease patients, especially in proximal
femur, was probably due to gait and posture abnormalities [9].
I am very much honored to inaugurate the Journal
‘Osteoporosis and Sarcopenia’. Thank you to the contributing
AFOS Countries including South Korea, Japan, Thailand,
Hong Kong, Macau, Malaysia, Singapore, Philippines, China,
and Taiwan. I also deeply appreciate all the Editorial Board
Members and Reviewers for the AFOS Journal (‘Osteoporosis
and Sarcopenia’). Hopefully, we can work together toward a
brighter future for research and treatment for osteoporosis in
the Asian countries.References
[1] Langdahl BL. New treatments of osteoporosis. Osteoporosis and Sarco-
penia 2015;1:4e21.
[2] Shiraki M, Tsugawa N, Okano T. Recent advances in vitamin K-dependent
Gla-containing proteins and vitamin K nutrition. Osteoporosis and Sar-
copenia 2015;1:22e38.
[3] Klein GL. The effect of glucocorticoids on bone and muscle. Osteoporosis
and Sarcopenia 2015;1:39e45.
[4] Matsumoto H, Hagino H, Sageshima H, Osaki M, Tanishima S,
Tanimura C. Diagnosis of knee osteoarthritis and gait variability increases
risk of falling for osteoporotic older adults: The GAINA study. Osteopo-
rosis and Sarcopenia 2015;1:46e52.Elsevier B.V. This is an open access article under the CC BY-NC-ND license
3Editorial / Osteoporosis and Sarcopenia 1 (2015) 2e3[5] Harada A, Ito S, Matsui Y, Sakai Y, Takemura M, Tokuda H, et al. Effect
of alendronate on muscle mass: Investigation in patients with osteoporosis.
Osteoporosis and Sarcopenia 2015;1:53e8.
[6] Iwamoto J, Kono H, Uzawa M. Comparative effect of alendronate and
teriparatide on bone mineral density and bone turnover among Japanese
postmenopausal women with history of fragility fractures: A clinical
practice-based observational study. Osteoporosis and Sarcopenia
2015;1:63e9.
[7] Amphansap T, Nitiwarangkul L. One-year mortality rate after osteoporotic
hip fractures and associated risk factors in Police General Hospital.
Osteoporosis and Sarcopenia 2015;1:75e9.
[8] Heo DR, Lee J, Park YS. Sacral insufficiency fracture with compression
fracture of the thoracolumbar spine: Analysis of coincidence rate and risk
factors. Osteoporosis and Sarcopenia 2015;1:70e4.[9] Kim KK, Kim TK, Won Y, Sung WS. A retrospective study on the
management of osteoporosis in Parkinson’s disease e A single institution,
preliminary study. Osteoporosis and Sarcopenia 2015;1:59e62.
Yoon-Sok Chung, MD, PhD, Editor-in-Chief
AFOS Journal Osteoporosis and Sarcopenia
Department of Endocrinology and Metabolism,
Ajou University School of Medicine, Suwon, South Korea
E-mail address: yschung@ajou.ac.kr.
